Clinical significance of ALK-1 gene abnormalities in diffuse large cell lymphoma

Clinical Medicine Insights: Oncology

Volumn 6, Issue , 2012, Pages 395-405

  Korashy, L ^a   El Zawahry, H ^b   Abdou, S ^a   Shahin, D ^c   Sherif, F ^a   Farrag, W ^a   Abdel Khalik, O ^a   Salem, H ^d   El Sebaaie, A ^e  

^a TANTA UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c MANSOURA UNIVERSITY   (Egypt)

^d Al Azhar University   (Egypt)

^e International Medical Center   (Egypt)

Author keywords

ALCL; ALK 1; FISH; IHC

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD15 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; COBALT 60; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ALK 1 GENE; ALOPECIA; ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INFECTION; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER TOXICITY; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; ORAL MUCOSITIS; OVERALL SURVIVAL; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN EXPRESSION; VOMITING;

EID: 84870908740     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.4137/CMO.S9920     Document Type: Article

References (62)

1. Mohammad RM, Al-Katib A, Aboukameel A, Doerge DR. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Mol Cancer Ther. 2003;2(12): 1361-8.
2. Lossos IS and Morgensztern D. Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2006;24(6):995-1007.
3. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-47.
4. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-82.
5. Stoica GE, Kuo A, Aigner A, et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem. 2001; 276(20):16772-9.
6. Naoe T, Suzuki T, Kiyoi H, Urano T. Nucleophosmin: a versatile molecule associated with hematological malignancies. Cancer Sci. 2006;97(10): 963-9.
7. Trinei M, Lanfrancone L, Campo E, et al. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res. 2000;60(4):793-8.
8. Maes B, Enrijk VV, Wlodarska I, et al. The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells. Am J Pathol. 2001; 158(6):2185-93.
9. Salaverria I, Beà S, Lopez-Guillermo A, et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol. 2008;140(5):516-26.
10. Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J. 2009;420(3): 345-61.
11. Rassidakis GZ, Goy A, Medeiros LJ, et al. Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma. Clin Cancer Res. 2003;9(6):2213-20.
12. Gregory SA, Trumper L. Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes? Ann Oncol. 2005;16(9):1413-24.
13. Piva R, Pellegrino E, Mattioli M, et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genes. J Clin Invest. 2006;116(12):3171-82.
14. Kelleher FC, McDermott R. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. Eur J Cancer. 2010; 46(13):2357-68.
15. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1): 11-23.
16. Remstein ED, Kurtin PJ, Buño I, et al. Diagnostic utility of fluorescence in situ hybridization in mantle-cell lymphoma. Br J Haematol. 2000;110(4): 856-62.
17. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
18. Jaccard J, Becker MA. Statistics for the behavioural sciences. 1997 3rd ed.
19. Sehn LH. Optimal use of prognostic factors in non-Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2006:295-302.
20. Barreca A, Lasorsa E, Riera L, et al. Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol. 2011;47(1):R11-R23. Print Aug 2011.
21. Tartari CJ, Gunby RH, Coluccia AM, et al. Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. J Biol Chem. 2008;283(7):3743-50.
22. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood. 1998; 91(6):2076-84.
23. El-Bolkainy N, Nouh A, El-bolkainy T. Topographic pathology of cancer. 3rd ed. The National Cancer Institute, Cairo University. 2005;1-7:157-70.
24. Ibrahim AS, Seif-El Din IA, Ismail K, Hablas A, et al. Cancer in Egypt, Gharbiah: Terminal Report of 2000-2 Gharbiah Population-Based Cancer Registry, 2nd ed. 2007.
25. Prosnitz LR, Andrea NG. Non-Hodgkin's lymphoma. Perez and Brady's: Principles and Practice of Radiation Oncology, 5th ed. Lippincott Co., Philadelphia; 2008:1739-60.
26. Pulford K, Falini B, Banham AH, et al. Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood. 2000;96(4):1605-7.
27. Wunderlich A, Kloess M, Reiser M, et al. Practicability and acute hematological toxicity of 2-and 3-weekly CHOP and CHOEP chemotherapy for aggressive non- Hodgkin's lymphoma: results from the NHL-B trial of the German high-grade non-Hodgkin's lymphoma study group (DSHNHL). Ann Oncol. 2003;4(6):881-93.
28. El-Gantitry MM, El-Mongy M, El-Naggar M. Assessment of treatment methods and results of adult non-Hodgkin's lymphoma of waldeyer's ring. Med J Cairo Univ. 1998;66(4):817-25.
29. Mokhtar N, Gouda I, Adel I. Cancer Pathology Registry 2003-4 and Time Trend Analysis, Department of Pathology, The National Cancer Institute, Cairo University; 2007:46-50.
30. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene. 2004;23(38):6524-34.
31. Itoh K, Ohtsu T, Wakita H, et al. Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma. Ann Oncol. 2000;11(10):1241-7.
32. Pfreundschuh M, Trümper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of DSHNHL. Blood. 2004;104(3):634-41.
33. Pfreundschuh M, Trümper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas results of the NHL-BI trial of DSHNHL. Blood. 2004;104(3):626-33.
34. Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999;93(8):2697-706.
35. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93(11):3913-21.
36. Drexler HG, Gignac SM, von Wasielewski R, Werner M, Dirks WG. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia. 2000;14(9):1533-59.
37. Savage KJ, Chanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15(10):1467-75.
38. el Sawi RM. Molecular detection of t(2;5)(p23;q35) chromosomal translocation; Bcl-6 and clusterin protein expression in large cell lymphomas. M.D. Thesis, Faculty of Medicine, Benha University; 2005.
39. Rizvi MA, Evens AM, Tallman MS, Nelson BP, Rosen ST. T-cell non-Hodgkin lymphoma. Blood. 2006;107(4):1255-64.
40. Falini B, Nicoletti I, Bolli N, et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica. 2007;92(4):519-32.
41. Liang X, Meech SJ, Odom LF, et al. Assessment of t(2;5)(p23;q35) translocation and variants in pediatric ALK+ anaplastic large cell lymphoma. Am J Clin Pathol. 2004;121(4):496-506.
42. Colleoni GWB, Bridge JA, Garicochea B, Liu J, Filippa DA, Ladanyi M. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am J Pathol. 2000;156(3):781-9.
43. Kadin ME, Morris SW. The t(2;5) in human lymphomas. Leuk Lymphoma. 1998;29(3-4):249-56.
44. Kutok JL, Aster JC. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J Clin Oncol. 2002;20(17): 3691-702.
45. Gascoyne RD, Lamant L, Martin-Subero JI, et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood. 2003;102(7):2568-73.
46. Lee HW, Kim K, Kim W, Ko YH. ALK-positive diffuse large B-cell lymphoma report of three cases. Hematol Oncol. 2008;26(2):108-13.
47. Beltran B, Castillo J, Salas R, et al. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol. 2009;2:11.
48. Falini B, Bigerna B, Fizzotti M, et al. ALK expression defines a distinct group of T/Null lymphomas (ALK Lymphomas) with a wide morphological spectrum. Am J Pathol. 1998;153(3):875-86.
49. Mathew P, Sanger WG, Weisenburger DD, et al. Detection of the t(2;5)(p23;q35) and NPM-ALK fusion in non-Hodgkin's lymphoma by two-color fluorescence in situ hybridization. Blood. 1997;89(5):1678-85.
50. Cessna MH, Zhou H, Sanger WG, Perkins SL. Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: A Study of 135 Cases. Mod Pathol. 2002;15(9):931-8.
51. Paternoster SF, Brockman SR, McClure RF, et al. A new method to extract nuclei from paraffin-embedded tissue to study lymphomas using interphase fluorescence in situ hybridization. Am J Pathol. 2002;160(6):1967-72.
52. Cataldo KA, Jalal SM, Law ME, et al. Detection of t(2;5) in anaplastic large cell lymphoma: comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue. Am J Surg Pathol. 1999;23(11): 1386-92.
53. Fan YS, Rizkalla K. Comprehensive cytogenetic analysis including multicolor spectral karyotyping and interphase fluorescence in situ hybridization in lymphoma diagnosis, a summary of 154 cases. Cancer Genet Cytogenet. 2003;143(1):73-9.
54. Leoncini L, Lazzi S, Scano D, et al. Expression of the ALK protein by anaplastic large-cell lymphomas correlates with high proliferative activity. Int J Cancer. 2000;86(6):777-81.
55. Fan YS, Rizkalla K. Comprehensive cytogenetic analysis including multicolor spectral karyotyping and interphase fluorescence in situ hybridization in lymphoma diagnosis, a summary of 154 cases. Cancer Genet Cytogenet. 2003;143(1):73-9.
56. Weisenburger DD, Anderson JR, Diebold J, et al. Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin's lymphoma classification project. Am J Hematol. 2001;67:172-8.
57. Colleoni GWB, Bridge JA, Garicochea B, Liu J, Filippa DA, Ladanyi M. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23;q35). Am J Pathol. 2000;156(3):781-9.
58. Pfreundschuh M, Trümper L, Kloess M, Schmits R, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of DSHNHL. Blood. 2004;104(3):634-41.
59. Pronzato P, Lionetto R, Botto F, Pensa F, Tognoni A. High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non-Hodgkin's lymphoma: a phase II study. Br J Cancer. 1998;78:777-80.
60. Gregory SA, Case DC, Bosserman L, et al. Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study. Clin Lymphoma. 2003;4(2):93-8.
61. Kaplan LD. Clinical Management of peripheral T-cell Lymphoma. Amer Soc Clin Oncol. 2007:1092-9118/07/445-60.
62. Bonvini P, Zorzi E, Mussolin L, et al. The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity. Haematologica. 2009;94(7):944-55.